STOCK-BASED COMPENSATION [Text Block] | 6. STOCK-BASED COMPENSATION Stock-based compensation includes grants of stock options and purchase warrants to eligible directors, employees and consultants as determined by the Board of Directors. Stock option plans Stock warrants Valuation of awards 1. Service-based; 2. Performance-based; and 3. Market-based. The Company used the following assumptions to estimate the fair values of the options granted for the quarters ended: March 31, 2017 March 31, 2016 Dividend yield - - Expected volatility 117.37 – 148.20% 132.45% - 164.23% Risk-free interest rate 0.52 – 1.48% 0.30 - 1.08% Expected life (years) 0.10 – 2.10 0.00 - 3.20 Inputs used in these models are determined as follows: 1. The expected life represents the weighted-average period the awards are expected to remain outstanding and is a derived output of the option pricing models. The expected life is impacted by all of the underlying assumptions and calibration of the Company’s models. 2. The requisite service period for market-based stock option awards is a derived output of the hybrid Monte Carlo-Trinomial Lattice model. 3. Volatility is based on the average historical volatility levels of a representative peer group or the Company’s common stock depending on the life of the options. 4. The risk-free interest rate is based on the implied yield available on U.S. Treasury zero- coupon issues over the equivalent contractual lives of the options. During the quarter ended March 31, 2017, stock based compensation activity was as follows: a) On December 27, 2016, the Company’s Board of Directors unilaterally determined to amend 1,367,197 stock options by extending their expiration dates and reducing their exercise price to $0.08 per share. The options were granted on various dates between 2009 and 2011 and had a weighted average exercise price of $0.61 per share. The expiration dates of all of the options were extended to January 31, 2017. On January 17, 2017, the Board of Directors unilaterally determined to further extend the expiration dates and reduced exercise price period to February 17, 2017. The modification resulted in incremental compensation cost of $2,587. No options were exercised during the inducement period. Additionally, the Company’s Board of Directors unilaterally determined to amend 7,600,000 stock options by temporarily reducing their exercise price to $0.08 per share for a period ending January 31, 2017. The options were granted on various dates between 2010 and 2015 and had a weighted average exercise price of $0.56 per share. On January 17, 2017, the Board of Directors unilaterally determined to further extend the reduced exercise price period to February 17, 2017. After the inducement period the options are exercisable under their previous terms. During the inducement period, 100,000 stock options were exercised for gross proceeds of $8,000. Compensation cost related to the exercise was $2,028. The Company’s Board of Directors also unilaterally determined to amend 4,800,000 warrants by extending their expiration dates and reducing their exercise price to $0.08 per share. The warrants were granted to consultants on various dates between 2009 and 2011 and had a weighted average exercise price of $0.74 per share. The expiration dates of all of the warrants were extended to January 31, 2017. On January 17, 2017, the Board of Directors unilaterally determined to further extend the expiration dates and reduced exercise price period to February 17, 2017. The modification resulted in no incremental compensation cost. No warrants were exercised during the inducement period. Additionally, the Company’s Board of Directors unilaterally determined to amend 4,950,000 warrants by temporarily reducing their exercise price to $0.08 per share for a period ending January 31, 2017. The warrants were granted to consultants on February 26, 2016 and had a weighted average exercise price of $0.40 per share. On January 17, 2017, the Board of Directors unilaterally determined to further extend the reduced exercise price period to February 17, 2017. After the inducement period the warrants are exercisable under their previous terms. No warrants were exercised during the inducement period. b) On February 17, 2017, the Company granted 300,000 warrants to a consultant exercisable at a price of $0.14 per share for a period expiring on February 17, 2020. The warrants were issued in consideration for services provided. During the quarter ended March 31, 2016, stock based compensation activity was as follows: a) On March 25, 2016, the Company’s Board of Directors unilaterally determined to amend 3,067,197 stock options by extending their expiration dates. The options were granted at various dates between 2009 and 2015 and have a weighted average exercise price of $0.49 per share. The expiration dates of all of the options were extended to December 31, 2016. In all other respects, the terms and conditions of the options remain the same. b) On February 26, 2016, the Company granted 4,950,000 warrants to consultants exercisable at a price of $0.40 per share for a period expiring on February 28, 2020. The warrants were issued in consideration for services provided. 4,500,000 of the warrants were granted to NMC who is a related party as discussed in Note 10. The total expense related to the granting, vesting and modification of all stock-based compensation awards was $153,701 and $983,413 for the quarters ended March 31, 2017 and 2016, respectively. Such expenses are included in general and administrative expense and mineral exploration and evaluation expense on the consolidated statements of operations. For the quarter ended March 31, 2017, the Company received $58,000 from the exercise of stock options; the related tax benefit amounted to $26,600 and the intrinsic value was $76,000. For the quarter ended March 31, 2016, no stock options were exercised. The following table summarizes the Company’s stock-based compensation activity for the quarter ended March 31, 2017: Weighted Weighted Average Average Remaining Grant Weighted Contractual Aggregate Number of Date Fair Average Life Intrinsic Shares Value Exercise Price (Years) Value Outstanding, December 31, 2016 31,562,197 $ 0.20 $ 0.41 2.92 Options/warrants granted 300,000 0.08 0.14 2.88 Options/warrants expired (7,387,197 ) 0.39 0.60 - Options/warrants exercised (1,100,000 ) 0.41 0.05 - Outstanding, March 31, 2017 23,375,000 $ 0.13 $ 0.35 3.69 $ 403,500 Exercisable, March 31, 2017 12,025,000 $ 0.19 $ 0.45 2.22 $ - Aggregate intrinsic value represents the value of the Company’s closing stock price on the last trading day of the quarter ended in excess of the weighted-average exercise price multiplied by the number of options outstanding or exercisable. The following table summarizes the changes of the Company’s stock-based compensation awards subject to vesting during the quarter ended March 31, 2017: Weighted Average Number of Grant Date Shares Fair Value Unvested, December 31, 2016 11,350,000 $ 0.12 Granted - - Expired - - Vested - - Unvested, March 31, 2017 11,350,000 $ 0.12 As of March 31, 2017, there was $373,231 of total unrecognized compensation cost related to unvested stock-based compensation awards. The weighted average period over which this cost will be recognized was 0.59 years as of March 31, 2017. |